PMA
P990009: FLOSEAL MATRIX/FLOSEAL MATRIX HEMOSTATIC SEALANT/PROCEED HEMOSTATIC SEALANT
FDA PMA · Absorbable collagen hemostatic agent with thrombin · Baxter Healthcare Corp
Key facts
| PMA number | P990009 |
|---|---|
| Trade name | FLOSEAL MATRIX/FLOSEAL MATRIX HEMOSTATIC SEALANT/PROCEED HEMOSTATIC SEALANT |
| Generic name | Absorbable collagen hemostatic agent with thrombin |
| Applicant | Baxter Healthcare Corp |
| Owner/operator | BAXTER HEALTHCARE CORPORATION |
| Product code | PMX |
| Approval date | Dec 8, 1999 |
| Docket number | 00M-1229 |
| Notice date | Dec 8, 1999 |
| Establishment registration | 1417572 |
| FEI number | 1417572 |
At a glance
- 10–99 Supplements
- Nov 13, 2025 Latest supplement decision
- No Withdrawn
- Yes Summary of safety and effectiveness on file
- 10–99 UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA approvals
Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: